Clinical Trial Update: Ibrutinib in Treating Participants With Untreated High Risk Smoldering Mantle Cell Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating ibrutinib in untreated high-risk smoldering mantle cell lymphoma; the study is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma
• Smoldering Mantle Cell Lymphoma

Drugs mentioned

• Ibrutinib (ibrutinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Mantle Cell Lymphoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING